JP2024516998A - Shp2阻害剤とegfrチロシンキナーゼ阻害剤とを含む併用療法 - Google Patents

Shp2阻害剤とegfrチロシンキナーゼ阻害剤とを含む併用療法 Download PDF

Info

Publication number
JP2024516998A
JP2024516998A JP2023567923A JP2023567923A JP2024516998A JP 2024516998 A JP2024516998 A JP 2024516998A JP 2023567923 A JP2023567923 A JP 2023567923A JP 2023567923 A JP2023567923 A JP 2023567923A JP 2024516998 A JP2024516998 A JP 2024516998A
Authority
JP
Japan
Prior art keywords
inhibitor
egfr
cancer
compound
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023567923A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024516998A5 (cg-RX-API-DMAC10.html
Inventor
ショジャエイ,ファーボッド
エム. リコノ,ジル
グデノフ,ロバート
ギリングス,ミレイユ
Original Assignee
フヤバイオ インターナショナル,エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by フヤバイオ インターナショナル,エルエルシー filed Critical フヤバイオ インターナショナル,エルエルシー
Publication of JP2024516998A publication Critical patent/JP2024516998A/ja
Publication of JP2024516998A5 publication Critical patent/JP2024516998A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2023567923A 2021-05-05 2022-05-04 Shp2阻害剤とegfrチロシンキナーゼ阻害剤とを含む併用療法 Pending JP2024516998A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163184697P 2021-05-05 2021-05-05
US63/184,697 2021-05-05
US202263320991P 2022-03-17 2022-03-17
US63/320,991 2022-03-17
PCT/US2022/027693 WO2022235815A1 (en) 2021-05-05 2022-05-04 Combination therapies comprising shp2 inhibitors and egfr tyrosine kinase inhibitors

Publications (2)

Publication Number Publication Date
JP2024516998A true JP2024516998A (ja) 2024-04-18
JP2024516998A5 JP2024516998A5 (cg-RX-API-DMAC10.html) 2025-05-14

Family

ID=83932546

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023567923A Pending JP2024516998A (ja) 2021-05-05 2022-05-04 Shp2阻害剤とegfrチロシンキナーゼ阻害剤とを含む併用療法

Country Status (8)

Country Link
US (1) US20220370456A1 (cg-RX-API-DMAC10.html)
EP (1) EP4334317A4 (cg-RX-API-DMAC10.html)
JP (1) JP2024516998A (cg-RX-API-DMAC10.html)
AU (1) AU2022270106A1 (cg-RX-API-DMAC10.html)
CA (1) CA3217092A1 (cg-RX-API-DMAC10.html)
IL (1) IL308225A (cg-RX-API-DMAC10.html)
MX (1) MX2023012929A (cg-RX-API-DMAC10.html)
WO (1) WO2022235815A1 (cg-RX-API-DMAC10.html)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019183367A1 (en) * 2018-03-21 2019-09-26 Relay Therapeutics, Inc. Shp2 phosphatase inhibitors and methods of use thereof
WO2020177653A1 (zh) * 2019-03-04 2020-09-10 勤浩医药(苏州)有限公司 吡嗪类衍生物及其在抑制shp2中的应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
CA2219361C (en) 1995-04-27 2012-02-28 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP1972194A1 (en) 1996-12-03 2008-09-24 Amgen Fremont Inc. Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom
WO1999029888A1 (en) 1997-12-05 1999-06-17 The Scripps Research Institute Humanization of murine antibody
WO2015050345A1 (en) 2013-10-01 2015-04-09 Lg Electronics Inc. Control apparatus for mobile terminal and control method thereof
PT3468972T (pt) 2016-06-14 2020-08-21 Novartis Ag Compostos e composições para inibir a atividade da shp2
CN110730678B (zh) * 2017-01-10 2022-07-15 诺华股份有限公司 包含alk抑制剂和shp2抑制剂的药物组合
US11033547B2 (en) * 2019-03-07 2021-06-15 Merck Patent Gmbh Carboxamide-pyrimidine derivatives as SHP2 antagonists
EP4288057A4 (en) * 2021-02-05 2025-03-12 Verastem, Inc. Combination therapy for treating abnormal cell growth
WO2022235822A1 (en) * 2021-05-05 2022-11-10 Huabio International, Llc Shp2 inhibitor monotherapy and uses thereof
CA3217084A1 (en) * 2021-05-05 2022-11-10 Farbod Shojaei Combination therapies comprising shp2 inhibitors and pd-1 inhibitors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019183367A1 (en) * 2018-03-21 2019-09-26 Relay Therapeutics, Inc. Shp2 phosphatase inhibitors and methods of use thereof
WO2020177653A1 (zh) * 2019-03-04 2020-09-10 勤浩医药(苏州)有限公司 吡嗪类衍生物及其在抑制shp2中的应用

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
CANCER IMMUNOL RES, vol. 3(8), JPN6026017801, 2015, pages 936 - 945, ISSN: 0005852945 *
CANCER RES, vol. Vol.80,Issue21, JPN6026017797, 2020, pages 4840 - 4853, ISSN: 0005852939 *
CLIN CANCER RES, vol. Volume27,Issue1, JPN6026017799, January 2021 (2021-01-01), pages 342 - 354, ISSN: 0005852942 *
ELIFE, vol. e58204, JPN6026017809, 2020, pages 1 - 29, ISSN: 0005852940 *
JOURNAL OF THORACIC ONCOLOGY, vol. Volume14,Issue10,Supplement,P1.17-08, JPN6026017798, 2019, ISSN: 0005852941 *
JTO CLINICAL AND RESEARCH REPORTS, vol. Volume1,Issue4,100084, JPN6026017800, 2020, pages 1 - 11, ISSN: 0005852944 *
RESEARCH SQUARE,SHP2 INHIBITION ENHANCES THE ANTICANCER EFFECT OF OSIMERTINIB IN EGFR T790M MUTANT L, JPN6026017806, March 2021 (2021-03-01), ISSN: 0005852943 *

Also Published As

Publication number Publication date
AU2022270106A1 (en) 2023-12-14
US20220370456A1 (en) 2022-11-24
WO2022235815A1 (en) 2022-11-10
EP4334317A4 (en) 2025-03-05
CA3217092A1 (en) 2022-11-10
MX2023012929A (es) 2023-11-13
EP4334317A1 (en) 2024-03-13
IL308225A (en) 2024-01-01

Similar Documents

Publication Publication Date Title
US12390469B2 (en) SHP2 inhibitor monotherapy and uses thereof
JP7075928B2 (ja) フェニレート誘導体、調製及び医薬組成物及び使用
US20100104567A1 (en) Pharmaceutical composition
WO2006074428A2 (en) Cxcr4 antagonists for the treatment of medical disorders
EA032509B1 (ru) Замещенные индазолы, способы их получения, содержащие их фармацевтические препараты и их применение для получения лекарственных средств
JP7660801B2 (ja) 脳透過性btk又はher2阻害剤としての化合物およびその製造方法と応用
CN112672744A (zh) 抑制二氢乳清酸脱氢酶的方法和组合物
TWI757726B (zh) 4(1h)-奎諾酮衍生物及其用途
CA2966452A1 (en) Substituted bicyclic compounds as bromodomain inhibitors
CN114246864B (zh) Csf1r激酶抑制剂及其用途
US20240182429A1 (en) Heterocyclic compound as tyk2 pseudokinase domain inhibitor, synthetic method, and use
US12097203B2 (en) Combination therapies comprising SHP2 inhibitors and PD-1 inhibitors
TW202214594A (zh) 含硫異吲哚啉類衍生物、其製備方法及其在醫藥上的應用
JP2021514955A (ja) プロテアソーム関連ユビキチン受容体rpn13機能を阻止する低分子およびその使用法
WO2022204721A1 (en) Alk-5 inhibitors and uses thereof
CN117677619A (zh) 包含shp2抑制剂和pd-1抑制剂的联合疗法
CN117642398A (zh) 包含shp2抑制剂和egfr酪氨酸激酶抑制剂的联合疗法
US20220370456A1 (en) Combination therapies comprising shp2 inhibitors and egfr tyrosine kinase inhibitors
HK40108830A (en) Combination therapies comprising shp2 inhibitors and egfr tyrosine kinase inhibitors
HK40108828A (en) Combination therapies comprising shp2 inhibitors and pd-1 inhibitors
HK40108829A (en) Shp2 inhibitor monotherapy and uses thereof
CN101137379B (zh) 用于治疗医学病症的cxcr4拮抗剂
KR20230072446A (ko) 암의 치료를 위한 인돌아민 2,3-디옥시게나아제 저해제와 면역체크포인트 억제제의 상승적 조합
TW202442228A (zh) 作為tyk2抑制劑的雜環化合物及合成與應用
HK40043086A (en) Methods and compositions for inhibition of dihydroorotate dehydrogenase

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240322

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250502

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250502

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260416

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260507

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260721